GSK Survey Reveals Gaps in Gynecologic Cancer Patient Experience

Stock.adobe.com

According to the results of a new survey from GSK, a majority of gynecologic cancer patients experience challenges accessing care and treatment.¹ The survey is part of GSK’s Your Cancer Is Our Challenge initiative, which is focused on uncovering the gaps in care that patients experience. These gaps aren’t just limited to treatment, but also emotional health as well.

In a press release, GSK senior vice president of oncology global product strategy Nina Mojas said, “At GSK, we continue to develop new therapies for patients with gynecologic cancers, yet we know there are also significant needs that treatment alone won’t address. The Your Cancer Is Our Challenge program is using real-world insights to show gaps and barriers in care, knowledge and support that will inspire future solutions that aim to address those challenges and improve patients’ lives.”

In the same press release, Jennifer Garam, an ovarian cancer survivor, said, “Being diagnosed with a gynecologic cancer, such as ovarian cancer, impacts every aspect of your life. Beyond medical treatment, patients with gynecologic cancers have many other needs that also have to be addressed, such as access to information, resources and the right psychosocial support. GSK’s Your Cancer Is Our Challenge is an important step forward in identifying these key challenges and barriers—so they can be addressed and overcome.”

In related news, GSK announced in late October that it had entered into an agreement with Chimagen Biosciences to acquire CMG1A46, a T cell-engager. This acquisition was made to expand GSK’s immunology pipeline.²

In a press release issued at the time, GSK’s chief scientific officer said, “Through our work in systemic lupus erythematosus and lupus nephritis, we increasingly understand the underlying drivers of B cell-driven diseases. As a novel therapeutic option directed at deep B cell depletion, CMG1A46 offers exciting potential which we are pleased to take forward to address unmet need in lupus and related autoimmune conditions.”

Chimagen CEO Zhenhao Zhou said, “We are excited by the potential of CMG1A46 to improve the lives of patients suffering from autoimmune conditions and grateful to have GSK accelerate that vision. This agreement provides further validation of our proprietary T cell-engager platform, and we are eager to continue our mission of developing novel multi-specific antibody therapeutics.”

In October, GSK also announced a partnership with Cambridge University to collaborate on kidney and respiratory diseases.³ At the time, Wood said, “Collaboration is at the heart of scientific progress and is fundamental to how we do R&D at GSK. We’re excited to build on our existing work with the University of Cambridge to further this world-leading scientific and technological capability in the UK. By bringing together Cambridge’s expertise and our own internal capabilities, including understanding of the immune system and the use of AI to accelerate drug development, we have an opportunity to help patients struggling with complex disease.”

Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, also said, “The University sits at the heart of Europe’s leading life sciences cluster, where excellent research and the NHS’s clinical resources combine with the talent generated by the many innovative bioscience companies that call Cambridge home. Through this very important collaboration with GSK, Cambridge will be able to drive economic growth for the UK while improving the health of people in this country and around the world.”

Sources

1. New GSK-Sponsored Survey Reveals Unique Gaps in Care and Support Facing Patients with Gynaecologic Cancers. GSK. November 12, 2024. https://www.gsk.com/en-gb/media/press-releases/new-gsk-sponsored-survey-reveals-unique-gaps-in-care-and-support-facing-patients-with-gynaecologic-cancers/
2. GSK Enters Agreement to Acquire CMG1A46 from Chimagen Biosciences to Expand Immunology Pipeline. GSK. October 29, 2024. Accessed November 14, 2024. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences/
3. GSK and Cambridge University Announce New Five-Year Collaboration in Kidney and Respiratory Disease. GSK. October 21, 2024. Accessed November 14, 2024. https://www.gsk.com/en-gb/media/press-releases/gsk-and-cambridge-university-announce-new-five-year-collaboration-in-kidney-and-respiratory-disease/